TCR Reserved and Power3 SPPL3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TCR Reserved and Power3 SPPL3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy, covering 2026-03-16 to 2026-03-16. Get the full timeline:
Most recent: Clinical Trial Update: TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL [Phase 1, Phase 2]